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A globally suppressed T cell function has been described
for cancer patients including patients with chronic lym-
phatic leukemia (CLL) or multiple myeloma (MM). This
has been mainly associated with inhibitory factors
released by the tumor cells, while the role of recently char-
acterized regulatory immune cells is not understood. Sev-
eral different regulatory T cells such as CD4+ CD25+ T cells
(Treg), TGFβ producing TH3 or IL-10 producing TR1 cells
have been described in murine models, and Treg cells have
also been implicated in the control of graft versus host dis-
ease after allogeneic transplantation in humans. In con-
trast, little is known about frequencies and function of
regulatory cells in leukemias and lymphomas. To address
this issue we have analyzed 82 peripheral blood samples
from 24 CLL patients, 18 MM patients and 26 healthy
individuals. By assessing CD4+ CD25+ T cells we estab-
lished a strongly significant increase of this subpopulation
in both CLL (13 ± 7% mean ± SD, p < 0.01) and MM (13
± 9%, p < 0.01) when compared to healthy individuals
(3.5 ± 1.5%). While CDC4+ CD25+ T cells could also com-
prise previously activated T cells, the expression of CTLA4
has been associated with Treg cells. In fact, 80± 14% respec-
tively 67± 26% of CD4+ CD25+ T cells in CLL resp. MM
were also CTLA4+, while only 30 ± 22% were found to be
positive in healthy individuals strongly suggesting that
these cells are mainly Treg cells. In contrast, using the
BDCA-4 specific antibody for Neuropilin-1, we were una-
ble to detect this molecule recently described on murine
Treg cells on any of our samples. Interestingly, a significant
proportion of CD4+ CD25+ T cells in CLL 28 ± 13% and
MM 22 ± 12% also expressed intracellular TGFβ, which
was only found in 6 ± 4% of these T cells in healthy indi-
viduals. Whether TGFβ production reflects a particular
activation status of Treg cells or whether these cells are a
defined subpopulation requires further investigation. By
analyzing co-expression of CCR7 and CD45RA we estab-
lished that the fraction of CD4+ CD25+ T cells was partic-
ularly increased in the naïve and the central memory pool
in peripheral blood of CLL and MM patients. Next we
assessed T cell activation as a function of Treg cells. As
expected, there was already a significantly decreased pro-
liferative response of CD4+ T cells in many CLL patients
even when CD25+ cells were depleted. These findings are
most likely explained by chronic exposure to inhibitory
cytokines as well as Treg cells. However, even under these
conditions, coculture experiments of CD4+ CD25- and
CD4+ CD25+ Treg cells supported the inhibitory role of Treg
cells in CLL. We therefore propose that immunotherapy in
any malignancy including CLL and MM characterized by
an increase of regulatory factors and cells will significantly
benefit from strategies inhibiting immune repression.
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